Languishing antibiotic discovery and flourishing antibiotic resistance have prompted the
development of alternative untapped sources for antibiotic discovery, including previously …

ClpC1 is an emerging new target for the treatment of Mycobacterium tuberculosis infections,
and several cyclic peptides (ecumicin, cyclomarin A, and lassomycin) are known to act on …

Summary The ClpC1: ClpP1P2 protease is a core component of the proteostasis system in
mycobacteria. To improve the efficacy of antitubercular agents targeting the Clp protease …

Drug-resistant tuberculosis (TB) has lent urgency to finding new drug leads with novel
modes of action. A high-throughput screening campaign of> 65,000 actinomycete extracts …

The ring-forming AAA+ hexamer ClpC1 associates with the peptidase ClpP1P2 to form a
central ATP-driven protease in Mycobacterium tuberculosis (Mtb). ClpC1 is essential for Mtb …

There is rapidly mounting evidence that intracellular proteases in bacteria are compelling
targets for antibacterial drugs. Multiple reports suggest that the human pathogen …

Mycobacterium tuberculosis is a pathogen of major global importance. Validated drug
targets are required in order to develop novel therapeutics for drug-resistant strains and to …

The emergence of methicillin-resistant Staphylococcus aureus isolates highlights the urgent
need to develop more antibiotics. ClpP is a highly conserved protease regulated by …

The Clp protease complex in Mycobacterium tuberculosis is unusual in its composition,
functional importance and activation mechanism. Whilst most bacterial species contain a …

We report the heterologous expression, structure, and antimicrobial activity of a lasso
peptide, ubonodin, encoded in the genome of Burkholderia ubonensis. The topology of …